NUT carcinoma: options by country

In clinical trials

• BET bromodomain inhibitors molibresib and birabresib; ZEN003694 with cisplatin-etoposide; ZEN003694 with abemaciclibClinical trialClinical trialInvestigationalUnited States · BRD4::NUTM1 and other NUTM1 fusion-driven disease underlying BET bromodomain inhibitor interest; no FDA-cleared predictive treatment biomarker beyond NUT carcinoma biology is stated for the investigational regimens; Metastatic or unresectable NUT carcinoma in clinical-trial settings. · PDQ explicitly frames these as clinical evaluation, and reported BET-inhibitor activity was limited. Do not represent these regimens as standard care or approved targeted therapy. Confidence/conflicts: High for the PDQ's limited-activity and under-clinical-evaluation framing; no approval claim is made. trial-registry listing only — does not establish approval, reimbursement, or eligibility National Cancer Institute — national cancer agency pediatric evidence summary
• BET bromodomain inhibitors molibresib and birabresib; ZEN003694 with cisplatin-etoposide; ZEN003694 with abemaciclibClinical trialClinical trialInvestigationalUnited States · BRD4::NUTM1 and other NUTM1 fusion-driven disease underlying BET bromodomain inhibitor interest; no FDA-cleared predictive treatment biomarker beyond NUT carcinoma biology is stated for the investigational regimens; Metastatic or unresectable NUT carcinoma in clinical-trial settings. · PDQ explicitly frames these as clinical evaluation, and reported BET-inhibitor activity was limited. Do not represent these regimens as standard care or approved targeted therapy. Confidence/conflicts: High for the PDQ's limited-activity and under-clinical-evaluation framing; no approval claim is made. trial-registry listing only — does not establish approval, reimbursement, or eligibility National Cancer Institute — national cancer agency pediatric evidence summary
• BET bromodomain inhibitors molibresib and birabresib; ZEN003694 with cisplatin-etoposide; ZEN003694 with abemaciclibClinical trialClinical trialInvestigationalUnited States · BRD4::NUTM1 and other NUTM1 fusion-driven disease underlying BET bromodomain inhibitor interest; no FDA-cleared predictive treatment biomarker beyond NUT carcinoma biology is stated for the investigational regimens; Metastatic or unresectable NUT carcinoma in clinical-trial settings. · PDQ explicitly frames these as clinical evaluation, and reported BET-inhibitor activity was limited. Do not represent these regimens as standard care or approved targeted therapy. Confidence/conflicts: High for the PDQ's limited-activity and under-clinical-evaluation framing; no approval claim is made. trial-registry listing only — does not establish approval, reimbursement, or eligibility National Cancer Institute — national cancer agency pediatric evidence summary
• Surgery, radiation therapy, chemotherapy, expert rare-tumor consultationClinical trialClinical trialInvestigationalUnited States · NUT protein testing; NUTM1 rearrangement, often BRD4::NUT fusion, described as confirmatory biology in the fetched NCI source; NUT carcinoma diagnosis and broad treatment discussion; surgery where feasible; radiation around surgery; chemotherapy for large tumors or spread. · NCI emphasizes rarity, lack of standard treatment, rapid growth, and potential treatment resistance. Do not imply any listed category is appropriate for all NUT carcinoma cases. Confidence/conflicts: High for broad treatment categories and no-standard-treatment caveat; no FDA approval claim is made. National Cancer Institute — national cancer agency rare-tumor information
• Surgery, radiation therapy, chemotherapy, expert rare-tumor consultationClinical trialClinical trialInvestigationalUnited States · NUT protein testing; NUTM1 rearrangement, often BRD4::NUT fusion, described as confirmatory biology in the fetched NCI source; NUT carcinoma diagnosis and broad treatment discussion; surgery where feasible; radiation around surgery; chemotherapy for large tumors or spread. · NCI emphasizes rarity, lack of standard treatment, rapid growth, and potential treatment resistance. Do not imply any listed category is appropriate for all NUT carcinoma cases. Confidence/conflicts: High for broad treatment categories and no-standard-treatment caveat; no FDA approval claim is made. National Cancer Institute — national cancer agency rare-tumor information
• Surgery, radiation therapy, chemotherapy, expert rare-tumor consultationClinical trialClinical trialInvestigationalUnited States · NUT protein testing; NUTM1 rearrangement, often BRD4::NUT fusion, described as confirmatory biology in the fetched NCI source; NUT carcinoma diagnosis and broad treatment discussion; surgery where feasible; radiation around surgery; chemotherapy for large tumors or spread. · NCI emphasizes rarity, lack of standard treatment, rapid growth, and potential treatment resistance. Do not imply any listed category is appropriate for all NUT carcinoma cases. Confidence/conflicts: High for broad treatment categories and no-standard-treatment caveat; no FDA approval claim is made. National Cancer Institute — national cancer agency rare-tumor information
• Surgery, radiation therapy, chemotherapy, expert rare-tumor consultationClinical trialClinical trialInvestigationalUnited States · NUT protein testing; NUTM1 rearrangement, often BRD4::NUT fusion, described as confirmatory biology in the fetched NCI source; NUT carcinoma diagnosis and broad treatment discussion; surgery where feasible; radiation around surgery; chemotherapy for large tumors or spread. · NCI emphasizes rarity, lack of standard treatment, rapid growth, and potential treatment resistance. Do not imply any listed category is appropriate for all NUT carcinoma cases. Confidence/conflicts: High for broad treatment categories and no-standard-treatment caveat; no FDA approval claim is made. National Cancer Institute — national cancer agency rare-tumor information
• Surgery, radiation therapy, chemotherapy, expert rare-tumor consultationClinical trialClinical trialInvestigationalUnited States · NUT protein testing; NUTM1 rearrangement, often BRD4::NUT fusion, described as confirmatory biology in the fetched NCI source; NUT carcinoma diagnosis and broad treatment discussion; surgery where feasible; radiation around surgery; chemotherapy for large tumors or spread. · NCI emphasizes rarity, lack of standard treatment, rapid growth, and potential treatment resistance. Do not imply any listed category is appropriate for all NUT carcinoma cases. Confidence/conflicts: High for broad treatment categories and no-standard-treatment caveat; no FDA approval claim is made. National Cancer Institute — national cancer agency rare-tumor information
• BAY 1238097 (brand not stated)Clinical trial · NCT02369029Clinical trialTrial only (registry)European Union · NUT (nuclear protein in testis)-midline carcinoma named in registry summary; specific fusion testing not stated in fetched fields; Advanced malignancies refractory to standard treatment, with no standard therapy available, where standard therapy was not a therapeutic option, refused, or experimental treatment judged clinically and ethically acceptable by the investigator. · Terminated first-in-human BET inhibitor study; condition list is broad neoplasms but fetched summary explicitly names NUT-midline carcinoma as a cohort context. Confidence/conflicts: Medium-high confidence because the fetched summary explicitly names NUT-midline carcinoma, but the formal condition field is broad neoplasms; no conflicting fetched source. Current access not established. ClinicalTrials.gov — trial registry
• BAY 1238097 (brand not stated)Clinical trial · NCT02369029Clinical trialTrial only (registry)European Union · NUT (nuclear protein in testis)-midline carcinoma named in registry summary; specific fusion testing not stated in fetched fields; Advanced malignancies refractory to standard treatment, with no standard therapy available, where standard therapy was not a therapeutic option, refused, or experimental treatment judged clinically and ethically acceptable by the investigator. · Terminated first-in-human BET inhibitor study; condition list is broad neoplasms but fetched summary explicitly names NUT-midline carcinoma as a cohort context. Confidence/conflicts: Medium-high confidence because the fetched summary explicitly names NUT-midline carcinoma, but the formal condition field is broad neoplasms; no conflicting fetched source. Current access not established. ClinicalTrials.gov — trial registry
• BI 894999 (brand not stated)Clinical trial · NCT02516553Clinical trialTrial only (registry)European Union · NUT carcinoma; specific NUTM1 fusion partner not stated in fetched registry fields; Advanced malignancies; registry summary states some countries allowed adolescents at least 15 years old with NUT carcinoma and notes no standard treatment exists for this rare aggressive form of cancer. · Completed early-phase dose-finding study; historical registry cell only; trial was not limited to NUT carcinoma. Confidence/conflicts: High confidence for NUT carcinoma condition, BI 894999 intervention, completed status, and listed regional sites; no conflicting fetched source. Current access not established. reimbursement not established in this jurisdiction ClinicalTrials.gov — trial registry
• BI 894999 (brand not stated)Clinical trial · NCT02516553Clinical trialTrial only (registry)European Union · NUT carcinoma; specific NUTM1 fusion partner not stated in fetched registry fields; Advanced malignancies; registry summary states some countries allowed adolescents at least 15 years old with NUT carcinoma and notes no standard treatment exists for this rare aggressive form of cancer. · Completed early-phase dose-finding study; historical registry cell only; trial was not limited to NUT carcinoma. Confidence/conflicts: High confidence for NUT carcinoma condition, BI 894999 intervention, completed status, and listed regional sites; no conflicting fetched source. Current access not established. reimbursement not established in this jurisdiction ClinicalTrials.gov — trial registry
• GSK525762 (molibresib; brand not stated in registry)Clinical trial · NCT01587703Clinical trialTrial only (registry)European Union · NUT protein ectopic expression by IHC and/or NUT gene translocation by FISH per trial inclusion text; NUT midline carcinoma subjects could be treatment naive or previously treated; other cohorts required tumor progression after at least one prior standard/approved chemotherapy, no approved therapy, or refusal of standard therapy. · Completed dose-escalation and expansion study; historical registry cell only, not evidence of current enrollment or routine access. Confidence/conflicts: High confidence for trial identity, NUT midline carcinoma eligibility, completed status, and country sites; no conflicting fetched source. Current availability not established. reimbursement not established in this jurisdiction ClinicalTrials.gov — trial registry
• GSK525762 (molibresib; brand not stated in registry)Clinical trial · NCT01587703Clinical trialTrial only (registry)European Union · NUT protein ectopic expression by IHC and/or NUT gene translocation by FISH per trial inclusion text; NUT midline carcinoma subjects could be treatment naive or previously treated; other cohorts required tumor progression after at least one prior standard/approved chemotherapy, no approved therapy, or refusal of standard therapy. · Completed dose-escalation and expansion study; historical registry cell only, not evidence of current enrollment or routine access. Confidence/conflicts: High confidence for trial identity, NUT midline carcinoma eligibility, completed status, and country sites; no conflicting fetched source. Current availability not established. reimbursement not established in this jurisdiction ClinicalTrials.gov — trial registry
• BAY 1238097 (brand not stated)Clinical trial · NCT02369029Clinical trialTrial only (registry)United Kingdom · NUT (nuclear protein in testis)-midline carcinoma named in registry summary; specific fusion testing not stated in fetched fields; Advanced malignancies refractory to standard treatment, with no standard therapy available, where standard therapy was not a therapeutic option, refused, or experimental treatment judged clinically and ethically acceptable by the investigator. · Terminated first-in-human BET inhibitor study; condition list is broad neoplasms but fetched summary explicitly names NUT-midline carcinoma as a cohort context. Confidence/conflicts: Medium-high confidence because the fetched summary explicitly names NUT-midline carcinoma, but the formal condition field is broad neoplasms; no conflicting fetched source. Current access not established. ClinicalTrials.gov — trial registry
• BAY 1238097 (brand not stated)Clinical trial · NCT02369029Clinical trialTrial only (registry)United Kingdom · NUT (nuclear protein in testis)-midline carcinoma named in registry summary; specific fusion testing not stated in fetched fields; Advanced malignancies refractory to standard treatment, with no standard therapy available, where standard therapy was not a therapeutic option, refused, or experimental treatment judged clinically and ethically acceptable by the investigator. · Terminated first-in-human BET inhibitor study; condition list is broad neoplasms but fetched summary explicitly names NUT-midline carcinoma as a cohort context. Confidence/conflicts: Medium-high confidence because the fetched summary explicitly names NUT-midline carcinoma, but the formal condition field is broad neoplasms; no conflicting fetched source. Current access not established. ClinicalTrials.gov — trial registry
• GSK525762 (molibresib; brand not stated in registry)Clinical trial · NCT01587703Clinical trialTrial only (registry)United Kingdom · NUT protein ectopic expression by IHC and/or NUT gene translocation by FISH per trial inclusion text; NUT midline carcinoma subjects could be treatment naive or previously treated; other cohorts required tumor progression after at least one prior standard/approved chemotherapy, no approved therapy, or refusal of standard therapy. · Completed dose-escalation and expansion study; historical registry cell only, not evidence of current enrollment or routine access. Confidence/conflicts: High confidence for trial identity, NUT midline carcinoma eligibility, completed status, and country sites; no conflicting fetched source. Current availability not established. reimbursement not established in this jurisdiction ClinicalTrials.gov — trial registry
• GSK525762 (molibresib; brand not stated in registry)Clinical trial · NCT01587703Clinical trialTrial only (registry)United Kingdom · NUT protein ectopic expression by IHC and/or NUT gene translocation by FISH per trial inclusion text; NUT midline carcinoma subjects could be treatment naive or previously treated; other cohorts required tumor progression after at least one prior standard/approved chemotherapy, no approved therapy, or refusal of standard therapy. · Completed dose-escalation and expansion study; historical registry cell only, not evidence of current enrollment or routine access. Confidence/conflicts: High confidence for trial identity, NUT midline carcinoma eligibility, completed status, and country sites; no conflicting fetched source. Current availability not established. reimbursement not established in this jurisdiction ClinicalTrials.gov — trial registry
• MT-4561 (brand not stated)Clinical trial · NCT06943521Clinical trialTrial only (registry)Japan · NUT carcinoma / NUTM1-rearranged context implied by disease label; specific fusion not stated in fetched registry fields; Advanced solid tumors; inclusion text states patients must have failed at least one prior therapy and have no standard treatment options demonstrated to provide clinical benefit, or be intolerant to or refuse further standard therapies. · Open-label first-in-human phase I/II dose-escalation/dose-optimization study; NUT carcinoma is one of multiple eligible solid tumor diagnoses; enrollment and eligibility depend on study criteria and site status. Confidence/conflicts: High confidence that the registry names NUT carcinoma, MT-4561, recruiting status, and Japan sites; no conflicting fetched source. Approval/access not established. reimbursement not established in this jurisdiction trial-registry listing only — does not establish approval, reimbursement, or eligibility ClinicalTrials.gov — trial registry
• MT-4561 (brand not stated)Clinical trial · NCT06943521Clinical trialTrial only (registry)Japan · NUT carcinoma / NUTM1-rearranged context implied by disease label; specific fusion not stated in fetched registry fields; Advanced solid tumors; inclusion text states patients must have failed at least one prior therapy and have no standard treatment options demonstrated to provide clinical benefit, or be intolerant to or refuse further standard therapies. · Open-label first-in-human phase I/II dose-escalation/dose-optimization study; NUT carcinoma is one of multiple eligible solid tumor diagnoses; enrollment and eligibility depend on study criteria and site status. Confidence/conflicts: High confidence that the registry names NUT carcinoma, MT-4561, recruiting status, and Japan sites; no conflicting fetched source. Approval/access not established. reimbursement not established in this jurisdiction trial-registry listing only — does not establish approval, reimbursement, or eligibility ClinicalTrials.gov — trial registry
• BI 894999 (brand not stated)Clinical trial · NCT02516553Clinical trialTrial only (registry)Korea · NUT carcinoma; specific NUTM1 fusion partner not stated in fetched registry fields; Advanced malignancies; registry summary states some countries allowed adolescents at least 15 years old with NUT carcinoma and notes no standard treatment exists for this rare aggressive form of cancer. · Completed early-phase dose-finding study; historical registry cell only; trial was not limited to NUT carcinoma. Confidence/conflicts: High confidence for NUT carcinoma condition, BI 894999 intervention, completed status, and listed regional sites; no conflicting fetched source. Current access not established. reimbursement not established in this jurisdiction ClinicalTrials.gov — trial registry
• BI 894999 (brand not stated)Clinical trial · NCT02516553Clinical trialTrial only (registry)Korea · NUT carcinoma; specific NUTM1 fusion partner not stated in fetched registry fields; Advanced malignancies; registry summary states some countries allowed adolescents at least 15 years old with NUT carcinoma and notes no standard treatment exists for this rare aggressive form of cancer. · Completed early-phase dose-finding study; historical registry cell only; trial was not limited to NUT carcinoma. Confidence/conflicts: High confidence for NUT carcinoma condition, BI 894999 intervention, completed status, and listed regional sites; no conflicting fetched source. Current access not established. reimbursement not established in this jurisdiction ClinicalTrials.gov — trial registry
• GSK525762 (molibresib; brand not stated in registry)Clinical trial · NCT01587703Clinical trialTrial only (registry)Korea · NUT protein ectopic expression by IHC and/or NUT gene translocation by FISH per trial inclusion text; NUT midline carcinoma subjects could be treatment naive or previously treated; other cohorts required tumor progression after at least one prior standard/approved chemotherapy, no approved therapy, or refusal of standard therapy. · Completed dose-escalation and expansion study; historical registry cell only, not evidence of current enrollment or routine access. Confidence/conflicts: High confidence for trial identity, NUT midline carcinoma eligibility, completed status, and country sites; no conflicting fetched source. Current availability not established. reimbursement not established in this jurisdiction ClinicalTrials.gov — trial registry
• GSK525762 (molibresib; brand not stated in registry)Clinical trial · NCT01587703Clinical trialTrial only (registry)Korea · NUT protein ectopic expression by IHC and/or NUT gene translocation by FISH per trial inclusion text; NUT midline carcinoma subjects could be treatment naive or previously treated; other cohorts required tumor progression after at least one prior standard/approved chemotherapy, no approved therapy, or refusal of standard therapy. · Completed dose-escalation and expansion study; historical registry cell only, not evidence of current enrollment or routine access. Confidence/conflicts: High confidence for trial identity, NUT midline carcinoma eligibility, completed status, and country sites; no conflicting fetched source. Current availability not established. reimbursement not established in this jurisdiction ClinicalTrials.gov — trial registry
• Standard-of-care anticancer treatment recorded retrospectively; may include surgery, radiotherapy, systemic chemotherapy, targeted therapy, and/or immunotherapy (no assigned study intervention)Clinical trial · NCT07459127Clinical trialTrial only (registry)China · NUT immunohistochemistry positivity and/or NUTM1 rearrangement/fusion per local pathology report; Patients with pathologically confirmed pulmonary NUT carcinoma diagnosed and/or treated at participating hospitals during the study period. · Observational retrospective record; no study-related intervention assigned or provided; should not be interpreted as access to a specific treatment. Confidence/conflicts: High confidence for China observational registry status and pulmonary NUT carcinoma eligibility; no conflicting fetched source. Treatment availability is not established. reimbursement not established in this jurisdiction trial-registry listing only — does not establish approval, reimbursement, or eligibility ClinicalTrials.gov — trial registry
• Standard-of-care anticancer treatment recorded retrospectively; may include surgery, radiotherapy, systemic chemotherapy, targeted therapy, and/or immunotherapy (no assigned study intervention)Clinical trial · NCT07459127Clinical trialTrial only (registry)China · NUT immunohistochemistry positivity and/or NUTM1 rearrangement/fusion per local pathology report; Patients with pathologically confirmed pulmonary NUT carcinoma diagnosed and/or treated at participating hospitals during the study period. · Observational retrospective record; no study-related intervention assigned or provided; should not be interpreted as access to a specific treatment. Confidence/conflicts: High confidence for China observational registry status and pulmonary NUT carcinoma eligibility; no conflicting fetched source. Treatment availability is not established. reimbursement not established in this jurisdiction trial-registry listing only — does not establish approval, reimbursement, or eligibility ClinicalTrials.gov — trial registry
• Standard-of-care anticancer treatment recorded retrospectively; may include surgery, radiotherapy, systemic chemotherapy, targeted therapy, and/or immunotherapy (no assigned study intervention)Clinical trial · NCT07459127Clinical trialTrial only (registry)China · NUT immunohistochemistry positivity and/or NUTM1 rearrangement/fusion per local pathology report; Patients with pathologically confirmed pulmonary NUT carcinoma diagnosed and/or treated at participating hospitals during the study period. · Observational retrospective record; no study-related intervention assigned or provided; should not be interpreted as access to a specific treatment. Confidence/conflicts: High confidence for China observational registry status and pulmonary NUT carcinoma eligibility; no conflicting fetched source. Treatment availability is not established. reimbursement not established in this jurisdiction trial-registry listing only — does not establish approval, reimbursement, or eligibility ClinicalTrials.gov — trial registry
• Standard-of-care anticancer treatment recorded retrospectively; may include surgery, radiotherapy, systemic chemotherapy, targeted therapy, and/or immunotherapy (no assigned study intervention)Clinical trial · NCT07459127Clinical trialTrial only (registry)China · NUT immunohistochemistry positivity and/or NUTM1 rearrangement/fusion per local pathology report; Patients with pathologically confirmed pulmonary NUT carcinoma diagnosed and/or treated at participating hospitals during the study period. · Observational retrospective record; no study-related intervention assigned or provided; should not be interpreted as access to a specific treatment. Confidence/conflicts: High confidence for China observational registry status and pulmonary NUT carcinoma eligibility; no conflicting fetched source. Treatment availability is not established. reimbursement not established in this jurisdiction trial-registry listing only — does not establish approval, reimbursement, or eligibility ClinicalTrials.gov — trial registry
• Standard-of-care anticancer treatment recorded retrospectively; may include surgery, radiotherapy, systemic chemotherapy, targeted therapy, and/or immunotherapy (no assigned study intervention)Clinical trial · NCT07459127Clinical trialTrial only (registry)China · NUT immunohistochemistry positivity and/or NUTM1 rearrangement/fusion per local pathology report; Patients with pathologically confirmed pulmonary NUT carcinoma diagnosed and/or treated at participating hospitals during the study period. · Observational retrospective record; no study-related intervention assigned or provided; should not be interpreted as access to a specific treatment. Confidence/conflicts: High confidence for China observational registry status and pulmonary NUT carcinoma eligibility; no conflicting fetched source. Treatment availability is not established. reimbursement not established in this jurisdiction trial-registry listing only — does not establish approval, reimbursement, or eligibility ClinicalTrials.gov — trial registry
• Standard-of-care anticancer treatment recorded retrospectively; may include surgery, radiotherapy, systemic chemotherapy, targeted therapy, and/or immunotherapy (no assigned study intervention)Clinical trial · NCT07459127Clinical trialTrial only (registry)China · NUT immunohistochemistry positivity and/or NUTM1 rearrangement/fusion per local pathology report; Patients with pathologically confirmed pulmonary NUT carcinoma diagnosed and/or treated at participating hospitals during the study period. · Observational retrospective record; no study-related intervention assigned or provided; should not be interpreted as access to a specific treatment. Confidence/conflicts: High confidence for China observational registry status and pulmonary NUT carcinoma eligibility; no conflicting fetched source. Treatment availability is not established. reimbursement not established in this jurisdiction trial-registry listing only — does not establish approval, reimbursement, or eligibility ClinicalTrials.gov — trial registry
• Standard-of-care anticancer treatment recorded retrospectively; may include surgery, radiotherapy, systemic chemotherapy, targeted therapy, and/or immunotherapy (no assigned study intervention)Clinical trial · NCT07459127Clinical trialTrial only (registry)China · NUT immunohistochemistry positivity and/or NUTM1 rearrangement/fusion per local pathology report; Patients with pathologically confirmed pulmonary NUT carcinoma diagnosed and/or treated at participating hospitals during the study period. · Observational retrospective record; no study-related intervention assigned or provided; should not be interpreted as access to a specific treatment. Confidence/conflicts: High confidence for China observational registry status and pulmonary NUT carcinoma eligibility; no conflicting fetched source. Treatment availability is not established. reimbursement not established in this jurisdiction trial-registry listing only — does not establish approval, reimbursement, or eligibility ClinicalTrials.gov — trial registry